Tal Medical said today it launched a dose optimization trial of its low field magnetic stimulation device designed to treat depression and other neuropsychiatric disorders. The company said it enrolled the 1st patient in the randomized, placebo-controlled 120-patient study, with data from the trial expected in early 2017. “Initiating the dose optimization study represents a significant […]
Fighting depression with medical devices: A podcast with Tal Medical’s Jan Skvarka
Tal Medical‘s roots go back to a serendipitous discovery at McLean Hospital more than a decade ago, when researchers working on bi-polar disorder reported that patients said they felt better after receiving an MRI. As it often does in medtech, that initial moment of discovery paved the way for years of development, eventually leading to […]
Medtech investment in MN falls back to earth | Medtech funding for the week of April 20, 2015
Tal Medical raises $14m for non-invasive anti-depression device
Tal Medical said today that it landed a $14 million Series B round it plans to use in backing clinical trials for its low-field magnetic stimulation technology as a non-invasive neurostimulation treatment for depression and bipolar disorder.
Acelity snares Smith & Nephew exec Agarwal | Personnel Moves
CeQur names medtech veteran as new CEO | Medtech personnel moves for the week of Apr. 14, 2014
CeQur gets new CEO from Becton Dickinson | Personnel Moves
April 11, 2014 by Arezu Sarvestani
Switzerland-based insulin delivery devices maker CeQur named medtech veteran Douglas Lawrence its new CEO, replacing James Peterson.
CeQur gets new CEO from Becton Dickinson | Personnel Moves
Switzerland-based insulin delivery devices maker CeQur named medtech veteran Douglas Lawrence its new CEO, replacing James Peterson.
Lawrence has spent more than 25 years in the medical device industry, most recently as vice president of the insulin injection business at Becton, Dickinson’s (NYSE:BDX) diabetes arm.
Tal Medical touts NIMH funding for device-based depression treatment
Tal Medical said it won funding from the National Institute of Mental Health, allowing the company to conduct a clinical trial of its Low Field Magnetic Stimulation technology in treating depression.
The LFMS technology is a non-invasive neuromodulation system that delivers magnetic stimulation to the brain through an external electromagnetic coil.
